| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.1 |
| Gross profit | 0.0 | 0.1 |
| Profit before tax | -3.6 | -7.6 |
| Net income | -3.6 | -7.6 |
| EPS (diluted, $ a share) | $-0.19 | $-0.69 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -17.5% |
|---|---|
| Gross margin | 55.2% |
10-Q filed with the SEC, NASDAQ: MGRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mangoceuticals, Inc.: key numbers
- Share price
- $0.1603Close, Nov 16
- Market cap
- $3.46M
- Shares outstanding
- 21.57MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Misc Health & Allied Services, NECSIC 8090
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mangoceuticals, Inc.
All →Mangoceuticals Other 8-K Filing
Mangoceuticals amended its Series B and Series C preferred stock designations and established a new Series D Preferred Stock class. The Series D Preferred Stock will rank senior to common stock and existing preferred classes regarding dividends and liquidation, though no shares were issued at the time of filing. The amendments include waivers from existing preferred holders to allow for the senior ranking and future Series D transactions.
Mangoceuticals Capital Raise
Mangoceuticals, Inc. received written consent from its Series B Preferred Stock holder to establish a new series of 8% Series D Convertible Cumulative Preferred Stock. The company plans to offer up to 1,000,000 shares of the Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B holder also approved an amendment to recognize the senior dividend and liquidation rights of the new Series D shares.
Mangoceuticals Capital Raise
Mangoceuticals, Inc. entered into a securities purchase agreement for a registered direct offering of 657,000 shares of common stock and accompanying warrants to purchase up to 657,000 additional shares. The offering was priced at $0.75 per unit, representing a 74% premium to the recent market close, and is expected to generate gross proceeds of approximately $492,750 for working capital and general corporate purposes.
- Counterparty
- certain investors
Mangoceuticals Divestiture to Two accredited investors for $2.5M
Mangoceuticals, Inc. sold a 25% ownership stake in its subsidiary, MangoRx IP Holdings, LLC, to two accredited investors for $2.5 million. The transaction was structured at the subsidiary level to raise capital for the commercialization of its antiviral technology (MGX-0024) without diluting the parent company's common stock.
- Value
- $2.5M
- Counterparty
- Two accredited investors